A contract manufacturer’s view of the formulation, testing and packaging decisions that sit behind four words in a product brief.
Written & researched by Creaton Poh, Founder, ORIZI Group · Technical input by ORIZI Group R&D Team · Fact-checked by ORIZI Group Editorial · Published by ORIZI Group · Last reviewed August 2026
Disclosure: This article is published by ORIZI Group and may refer to our own manufacturing experience, services and capabilities. External factual claims are supported by cited sources.
Quick answer: what does a sensitive-skin brief change in formulation?
A sensitive-skin brief changes the formulation’s constraints rather than its ingredient count. In practice we adjust four things: the surfactant or emulsifier system, the preservative system, the fragrance decision, and the concentration and delivery of any active. Each adjustment has a visible consequence for the brand — less foam, a shorter shelf life, a different scent profile, or slower visible results — so the useful conversation is about which trade-off the brand is willing to accept, not about removing ingredients.
Key takeaways
- “Sensitive skin” has no regulatory definition and no laboratory biomarker, so a sensitive-skin product is defined by what it is designed to avoid and what testing supports it — not by a fixed ingredient list.
- Reducing the ingredient count is not the same as reducing irritation potential. A short list can still contain a strong surfactant, a high-risk preservative or an unbuffered acid.
- The four levers that matter most in our development work are the cleansing or emulsifier system, the preservative system, the fragrance decision and the active concentration.
- “Fragrance-free” is a regulated statement in several markets, not a marketing adjective — and the European Union’s expanded fragrance-allergen labelling rule reached its first compliance date on 31 July 2026.
- Most sensitive-skin projects that go wrong in our experience fail on packaging compatibility or preservative efficacy, not on the active.
Scope and definitions
This article covers leave-on and rinse-off skincare and personal care formats developed under an OEM (Original Equipment Manufacturer) or ODM (Original Design Manufacturer) arrangement, with Malaysia and the wider ASEAN market as the reference regulatory context. It is a formulation and development perspective, not medical advice, and it does not address products intended to treat diagnosed skin disease — those fall outside the cosmetic category entirely.
Sensitive skin is defined by the International Forum for the Study of Itch as unpleasant sensations — stinging, burning, pain, itching and tingling — in response to stimuli that would not normally provoke such reactions, without visible lesions attributable to a skin disease. That definition matters for manufacturers because it is sensory and self-reported. A review of prevalence studies published in Frontiers in Medicine found no reliable diagnostic test and no correlation between reported symptoms and objective signs, with self-reported prevalence varying enormously by region — around 74.7% reporting some sensitivity in European surveys against roughly 23% of women surveyed in China (Misery et al., The Prevalence of Sensitive Skin).
Why “just use fewer ingredients” is usually the wrong instruction
The single most common instruction we receive on a sensitive-skin brief is to keep the ingredient list short. It is an understandable instinct and it is often counterproductive.
A formula with twelve ingredients can be considerably harsher than one with thirty-five. The irritation potential of a cosmetic sits in specific choices — which surfactant, at what concentration, at what pH, with what buffering, in what contact time — not in the length of the INCI list. Removing a humectant or a barrier lipid to shorten the list usually makes the finished product less comfortable, because those are the materials doing the buffering work.
There is also a preservation consequence. Stripping a formula down often removes ingredients that were contributing to the overall preservative system, which means the remaining preservative has to work harder, at a higher level, in a formula that is now more vulnerable. That is the opposite of the intended outcome.
The more productive brief is a constraint list rather than an ingredient-count target: which materials must be excluded, which sensory outcome is non-negotiable, and which testing the brand intends to run.
The four levers we actually pull
When a brief specifies sensitive skin, these are the four decisions that consume most of the development time, and the trade-off each one hands back to the brand.
| Lever | What changes in the formula | Trade-off the brand will feel |
|---|---|---|
| Cleansing / emulsifier system | Milder surfactant blends and gentler emulsifiers, with pH held closer to the skin’s own range | Less foam, a different rinse feel, and sometimes weaker makeup removal — the most common source of consumer complaints |
| Preservative system | Avoiding recognised sensitisers and reworking the system around the remaining permitted options | Narrower pH window, tighter packaging requirements, and a challenge test that has to be re-run whenever anything changes |
| Fragrance decision | True fragrance-free, or a fragrance built to exclude individually labelled allergens | An honest fragrance-free product smells of its own raw materials, which many buyers do not expect |
| Active concentration and delivery | Lower use levels, buffered acids, encapsulation or slower-release systems | Slower visible results, which has to be reflected in the marketing rather than argued with |
None of these levers is exotic. What makes sensitive-skin development slower than a conventional brief is that the four interact: changing the surfactant moves the pH, moving the pH changes which preservatives remain effective, and changing the preservative system means the compatibility and stability work starts again. This is the same interlocking-constraint problem we described for a very different format in why a melting body butter bar is harder to manufacture than a cream.
Fragrance-free, unscented, and the labelling change that landed on 31 July 2026
Fragrance is where sensitive-skin briefs most often collide with regulation, because the words have specific meanings.
“Unscented” and “fragrance-free” are not interchangeable. A product can be unscented — smelling of nothing in particular — while containing a masking fragrance to cover a raw-material odour. The European Commission’s technical document on cosmetic claims is explicit that a “free from perfume” claim should not be used when a product contains an ingredient exerting a perfuming function, regardless of that ingredient’s other functions in the formula (Technical document on cosmetic claims, Annex III).
The labelling picture also moved this year. Commission Regulation (EU) 2023/1545 expanded the list of fragrance substances that must be declared individually on the ingredient list from 24 to roughly 80, at concentrations above 0.001% in leave-on products and 0.01% in rinse-off products. Products placed on the EU market from 31 July 2026 must already comply, with stock already in the supply chain given until 31 July 2028 (Regulation (EU) 2023/1545, EUR-Lex). For a Malaysian manufacturer this is not directly binding — local notification follows the ASEAN Cosmetic Directive through the National Pharmaceutical Regulatory Agency (NPRA) — but it matters commercially, because brands built for export, and increasingly brands selling to informed local buyers, are asking for allergen declarations in the same format.
Our practical position is that a brand should decide early which of the three it actually wants: genuinely fragrance-free, fragranced but formulated to exclude the individually labelled allergens, or conventionally fragranced with the sensitivity claim dropped. Switching between them late in development is one of the more expensive changes a brief can make, because it reopens both the stability file and the label.
What we watch in our own development work
Based on ORIZI Group’s manufacturing experience across skincare and personal care formats, three things account for most of the schedule risk on a sensitive-skin project, and none of them is the active ingredient.
Preservative efficacy comes back to bite. When a brief excludes several commonly used preservatives, the remaining system usually works within a narrower pH window and is more sensitive to the rest of the formula. Every subsequent change — a new botanical extract, a different humectant, a packaging swap — is a reason to re-run the challenge test rather than assume the earlier result still holds.
Packaging is part of the formula. A reduced-preservative or preservative-light formula is far more dependent on the pack protecting it. An airless pump, a tube or a single-dose format is doing genuine microbiological work that an open jar does not do. We would rather agree the packaging direction at the formulation stage than be asked to make an already-approved formula survive a jar chosen for its shelf appeal. The same principle sits behind our product testing sequencing.
Sensory expectations need to be set before the first sample. A milder cleansing system foams less. A fragrance-free cream smells faintly of its emollients. These are predictable consequences of the brief, but if nobody says so in advance they arrive as disappointments at sample review and trigger a round of changes that undoes the mildness work. Setting the expectation costs one paragraph in a brief; not setting it has cost projects weeks.
We should be clear about the limits of that perspective: these are patterns we see in our own development pipeline, not published research, and they will not hold uniformly across every formula, factory or market.
Where sensitive-skin projects most often go wrong
- Treating the claim as a formulation shortcut. “For sensitive skin” is a claim that has to be supportable. In ASEAN markets, product claims must be justified by technical data or by the formulation itself, and that evidence has to be kept with the product information file — see the ASEAN Cosmetic Claim Guideline published by NPRA.
- Drifting into medical language. Sensitive-skin marketing slides easily into eczema, dermatitis or rosacea territory. The ASEAN guideline lists claims such as treating or preventing disease as outside the cosmetic category, and a product presented that way is no longer being notified as a cosmetic.
- Promising a guarantee. No cosmetic can promise the absence of an allergic reaction. The EU guidance states plainly that a “free from allergenic/sensitising substances” claim is not permitted, because complete absence of risk cannot be guaranteed.
- Skipping human tolerance testing. A stability file and a challenge test say nothing about how the product feels on reactive skin. Tolerance testing on human volunteers is a separate exercise, and it needs to be budgeted and scheduled rather than discovered late.
- Changing the formula after the testing. A tolerance result belongs to the exact formula that was tested. A late fragrance addition or preservative swap invalidates it.
Frequently asked questions
Is there a legal definition of “sensitive skin” for cosmetics in Malaysia?
No. Neither the ASEAN Cosmetic Directive nor Malaysian cosmetic guidelines define sensitive skin as a product category. What is regulated is the claim: any benefit stated on the product must be justified by technical data or by the formulation itself, and the supporting evidence must be held with the product information file for inspection.
Does a sensitive-skin formula cost more to develop?
Usually yes, though the increase generally comes from testing and iteration rather than raw materials. Excluding common preservatives and fragrance materials narrows the formulation space, which means more development rounds, and the tolerance and challenge testing sit on top of the standard stability programme. The exact figure depends on format, packaging and how many markets the product is intended for, so it should be quoted per project rather than estimated from a rule of thumb.
Can a product be both “for sensitive skin” and contain active ingredients?
Yes, and this is the core of what the industry calls “mild and mighty” formulating. The usual routes are a lower use level, a buffered or salt form of an acid, encapsulation, or a delivery system that slows release. The honest consequence is a slower visible result, which is a positioning decision for the brand rather than a formulation failure.
What testing supports a sensitive-skin claim?
Typically a human tolerance study on a panel that includes self-declared sensitive-skin participants, run under dermatological supervision, alongside the standard stability and preservative-efficacy work. A human repeat insult patch test (HRIPT) is the established method for irritation and sensitisation potential and runs over roughly six weeks in three phases. The right combination depends on the claim wording and the target market, so agree it before development rather than after.
Is “hypoallergenic” a safer claim to use than “for sensitive skin”?
It is generally a harder one. Under the European Commission’s guidance, “hypoallergenic” requires that the product was designed to minimise allergenic potential, that known allergens and allergen precursors are totally avoided, and that the responsible person holds scientifically robust and statistically reliable evidence of very low allergenic potential, reviewed continuously. It also does not guarantee the absence of an allergic reaction, and the product must not imply that it does.
Can an existing formula be converted to a sensitive-skin version?
Sometimes, but it is rarely a small edit. Removing the fragrance and softening the surfactant usually changes pH, viscosity and preservative performance together, which means the stability and challenge testing restart. In our experience it is worth comparing the cost of converting an existing base against developing a purpose-built one before assuming conversion is the cheaper route. Our sensitive-skin OEM development work usually starts with exactly that comparison.
Sources and references
- Misery L. et al., The Prevalence of Sensitive Skin, Frontiers in Medicine — IFSI definition, regional prevalence, and the absence of a reliable diagnostic test.
- European Commission, Technical document on cosmetic claims — Annex III on “free from” claims and Annex IV on “hypoallergenic”.
- Commission Regulation (EU) 2023/1545, EUR-Lex — expanded fragrance-allergen labelling and the 31 July 2026 / 31 July 2028 transitional dates.
- NPRA Malaysia, ASEAN Cosmetic Claim Guideline (Annex 1, Part 8) — the decision process for acceptable cosmetic claims and examples of unacceptable ones.
- Further reading, market perspective: Sensitive-Skin Claims in Cosmetics: What Buyers Must Verify on oemhallmark.com — an independent look at the same trend from the brand-owner and sourcing side.
- Related ORIZI reading: how hyaluronic acid works in skincare and why our R&D team is watching a new AI-designed collagen III active.
Update history
August 2026 — first published.
If you are working on a sensitive-skin product
We are interested in how other formulators and brand teams are handling the same trade-offs, particularly the fragrance decision now that the European allergen list has expanded. If you are weighing up a sensitive-skin brief and want to talk through the constraints before committing to a direction, the ORIZI sensitive-skin development team is happy to have that conversation — no obligation to build anything with us.
Source / inspired by: Azelis Personal Care, “Mild and mighty ingredients that power sensitive skin care”, and the Azelis Personal Care inspiration hub. This article is general manufacturing commentary and is not medical or regulatory advice — confirm claim wording, testing requirements and notification obligations with the relevant authority for your market before launch.
